

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A sustained-release pharmaceutical composition comprising granulocyte-colony stimulating factor (G-CSF) incorporated into a biocompatible polyol:oil suspension, wherein said suspension contains a thickener, and wherein said composition is prepared by a process which comprises:

(a) mixing a solution of G-CSF in a polyol to form a G-CSF:polyol mixture;

(b) suspending said G-CSF:polyol mixture in a mixture comprising a thickened oil to form a G-CSF:polyol:oil suspension wherein the level of said polyol in said suspension is in the range from 15%-30% by weight.

2. (previously presented) The composition of Claim 1 wherein said biocompatible polyol is selected from the group consisting of glycerol, erythritol, arabinose, xylose, ribose, inositol, fructose, galactose, maltose, and sucrose.

3. (previously presented) The composition of Claim 1 wherein said oil is selected from the group consisting of sesame, castor, cottonseed, canola, saffron, olive, peanut, sunflower seed, α -tocopherol, and ethyl oleate.

4. (previously presented) The composition of Claim 13 wherein the thickener is aluminum monostearate.

5. (previously presented) The composition of Claim 13 wherein the thickener is white wax.

6-7. (Cancelled)

8. (previously presented) A process for preparing sustained-release pharmaceutical compositions of G-CSF:polyol:oil suspensions which comprises:

(a) mixing a solution of G-CSF in a polyol to form a G-CSF:polyol mixture;

(b) suspending said G-CSF:polyol mixture in a mixture comprising a thickened oil to form a G-CSF:polyol:oil suspension wherein the level of said polyol in said suspension is in the range from 15%-30% by weight.

9-12. (Cancelled)

13. (previously presented) The composition of Claim 1 wherein the thickener is selected from the group consisting of polyvalent metal salts of organic acids, waxes and high viscosity oils.